MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

756.67M

Vuru Grade

31.00/100

Current Price

$11.07
-0.64 (-5.47%)

Company Metrics

  • P/E 13.83
  • P/S 7.93
  • P/B 2.28
  • EPS -1.28
  • Cash ROIC -52.09%
  • Cash Ratio 9.03
  • Dividend 0 / 0%
  • Avg. Vol. 485,371.00
  • Shares 68.35M
  • Market Cap. 756.67M

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Q2 2016 Earnings Forecast for Momenta Pharmaceuticals Inc. (MNTA) Issued By ...
BBNS - 17 hours ago
Momenta Pharmaceuticals logo Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) - Research analysts at Leerink Swann reduced their Q2 2016 EPS estimates for Momenta Pharmaceuticals in a report issued on Monday.
Momenta Pharmaceuticals Inc versus Retrophin Inc Head to Head Compare
CML News - Jul 22, 2016
Retrophin Inc has a substantially higher fundamental rating then Momenta Pharmaceuticals Inc which has an impact on the head-to-head comparison.
Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Motley Fool - Mar 4, 2016
What: Shares of Momenta Pharmaceuticals (NASDAQ:MNTA), a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P ...
Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today
Motley Fool - Feb 18, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) is down 11% at 12:00 p.m. EST Thursday after releasing fourth quarter earnings this morning.
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q4 2015 Results ... - Seeking Alpha
Ligand Pharmaceuticals Incorporated versus Momenta Pharmaceuticals Inc Head to ...
CML News - Jul 20, 2016
Ligand Pharmaceuticals Incorporated has a substantially higher fundamental rating then Momenta Pharmaceuticals Inc which has an impact on the head-to-head comparison.
Why Momenta Pharmaceuticals, Inc. Was Up Today
Motley Fool - Jan 8, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) was up as much as much as 11.7% today, eventually finishing up 6.8% after announcing a deal with Mylan (NASDAQ:MYL) to develop six biosimilar products.
Momenta, Mylan to Jointly Develop Six Biosimilars - Wall Street Journal
Momenta Pharmaceuticals Announces Date for Second Quarter 2016 Financial ...
Yahoo Finance - Jul 21, 2016
CAMBRIDGE, Mass., July 21, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ...
Investor Watch: Earnings and Street Rating Review for Momenta Pharmaceuticals ...
Engelwood Daily - Jul 27, 2016
Investors and analysts will be waiting to see if the company hits or misses earnings projections after the next earnings report. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is scheduled to next post quarterly results on or around 2016-08-04. The ...
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) Receives Consensus Rating of "Hold ...
Community Financial News - Jul 14, 2016
Momenta Pharmaceuticals logo Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) has been given a consensus rating of “Buy” by the eleven brokerages that are presently covering the firm.
Amarin Corporation plc versus Momenta Pharmaceuticals Inc Head to Head Compare - CML News
What's Next for Momenta Pharmaceuticals, Inc. After Today's Huge Decline?
Press Telegraph - Jul 27, 2016
The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is a huge mover today! About 350,455 shares traded hands. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has declined 27.31% since December 21, 2015 and is downtrending.